Cargando…

Treatment of rocuronium-induced anaphylaxis using sugammadex - A case report -

BACKGROUND: Perioperative anaphylaxis is a life-threatening clinical condition characterized by severe respiratory and cardiovascular manifestations. Neuromuscular blocking agents are the most common cause of anaphylaxis during anesthesia. CASE: We report a case of rocuronium-induced anaphylaxis tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sun-Min, Oh, Sei-hoon, Ryu, Seung-Ah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Anesthesiologists 2021
Materias:	Neuromuscular Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861895/ https://www.ncbi.nlm.nih.gov/pubmed/33348946 http://dx.doi.org/10.17085/apm.20074

Ejemplares similares

Chronic exposure to dexamethasone may not affect sugammadex reversal of rocuronium-induced neuromuscular blockade: an in vivo study on rats
por: Park, Ha Yeon, et al.
Publicado: (2023)

Effects of hydrocortisone-presensitized sugammadex on recovery from neuromuscular blockade induced by rocuronium: a rodent in vivo study
por: Choi, Hey-Ran, et al.
Publicado: (2022)

Sugammadex and rocuronium-induced anaphylaxis
por: Takazawa, Tomonori, et al.
Publicado: (2015)

Anaphylaxis induced by sugammadex and sugammadex-rocuronium complex -a case report-
por: Choi, Shu Chung, et al.
Publicado: (2020)

The use of sugammadex in an infant with prolonged neuromuscular blockade - A case report -
por: Kim, Hyunho, et al.
Publicado: (2022)

Successful management of rocuronium-induced anaphylaxis with sugammadex: A case report
por: Hung, Sheng-Kai, et al.
Publicado: (2022)

Sugammadex-induced anaphylactic shock
por: Kim, Ha-Jung, et al.
Publicado: (2020)

Possible mitigation of rocuronium-induced anaphylaxis after administration of sugammadex
por: Motamed, Cyrus, et al.
Publicado: (2012)

Adverse events of sugammadex that occurred in a Korean population
por: Han, Woong, et al.
Publicado: (2022)

Effects of rocuronium, sugammadex and rocuronium-sugammadex complex on coagulation in rats
por: Lima Cavalcanti, Ismar, et al.
Publicado: (2020)

Sugammadex associated profound bradycardia and sustained hypotension
por: Choi, Jae Moon, et al.
Publicado: (2020)

Anaphylactic shock after sugammadex administration, induced by formation of a sugammadex-rocuronium complex -a case report-
por: Kim, Gunn Hee, et al.
Publicado: (2019)

Sugammadex: Anaphylaxis: case report
Publicado: (2021)

Rocuronium-induced anaphylaxis: a case report
por: Takahashi, Kanako, et al.
Publicado: (2019)

Repeat dosing of rocuronium-sugammadex: unpredictable
por: Kim, Yoon-Hee
Publicado: (2014)

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study
por: Verboon, Christine, et al.
Publicado: (2021)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

A Meta-Analysis on the Effect of Dexamethasone on the Sugammadex Reversal of Rocuronium-Induced Neuromuscular Block
por: Koo, Chang-Hoon, et al.
Publicado: (2020)

Rocuronium bromide induced anaphylaxis in a child -A case report-
por: Jang, Young Ho, et al.
Publicado: (2010)

Whole-genome sequencing and the clinician: a tale of two cities
por: Foley, A Reghan, et al.
Publicado: (2014)

Untargeted metabolomics yields insight into ALS disease mechanisms
por: Goutman, Stephen A, et al.
Publicado: (2020)

Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B
por: Takahashi, Toshiaki, et al.
Publicado: (2013)

Autosomal dominant eccentric core disease caused by a heterozygous mutation in the MYH7 gene
por: Romero, Norma B, et al.
Publicado: (2014)

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients
por: Querin, Giorgia, et al.
Publicado: (2016)

Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation?
por: Prell, Tino, et al.
Publicado: (2016)

Imaging muscle as a potential biomarker of denervation in motor neuron disease
por: Jenkins, Thomas M, et al.
Publicado: (2018)

Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2018)

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
por: Imai, Tomihiro, et al.
Publicado: (2018)

Classifying Adverse Events Following Lower Limb Orthopaedic Surgery in Children With Cerebral Palsy: Reliability of the Modified Clavien-Dindo System
por: Zhou, Leena, et al.
Publicado: (2018)

Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy
por: Strauss, Kevin A., et al.
Publicado: (2018)

Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
por: Kaji, Ryuji, et al.
Publicado: (2019)

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
por: Diaz-Manera, Jordi, et al.
Publicado: (2018)

Differentiating lower motor neuron syndromes
por: Garg, Nidhi, et al.
Publicado: (2017)

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019)

Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2019)

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
por: Capodivento, Giovanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ibqharj2e55d8mj6k47m2745mr